Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16563090 | 0.98 | CA2 (0.40) | CA2ALDH1A1TSHRTDP1SLC22A2 | |
| SCHEMBL17996807 | 0.91 | SLC22A2 (0.35) | CA2ALDH1A1TSHRTDP1SLC22A2 | |
| Hydrochloric Acid SCHEMBL16563083 | 0.88 | KIF11 (0.42) | CA2ALDH1A1TSHRTDP1KIF11 | |
| SCHEMBL17997003 | 0.87 | ALDH1A1 (0.34) | CA2ALDH1A1TSHRTDP1GABRA1 | |
| SCHEMBL18012043 | 0.85 | BCHE (0.41) | CA2ALDH1A1TSHRTDP1KIF11 | |
| SCHEMBL16563077 | 0.84 | SLC22A2 (0.31) | CA2ALDH1A1TSHRTDP1SLC22A2 | |
| SCHEMBL17997006 | 0.78 | ACHE (0.41) | CA2KIF11 | |
| SCHEMBL19888150 | 0.71 | ACHE (0.44) | CA2ALDH1A1TSHRTDP1SLC22A2 | |
| SCHEMBL12963296 | 0.70 | RBP4 (0.34) | ALDH1A1TSHRTDP1 | |
| SCHEMBL29355273 | 0.68 | ALDH1A1 (0.63) | CA2ALDH1A1TSHRTDP1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374230-A1 | CROSSLINKED GEL FORMULATION | ESSILOR INTERNATIONAL (FR) | 2023-11-23 | — | — | US | disclosed |
| US-20230374230-A1 | CROSSLINKED GEL FORMULATION | ESSILOR INTERNATIONAL (FR) | 2023-11-23 | — | — | US | disclosed |
| US-20230220274-A1 | ELECTROCHROMIC SOLUTION | ESSILOR INTERNATIONAL (FR) | 2023-07-13 | — | — | US | disclosed |
| US-20230220274-A1 | ELECTROCHROMIC SOLUTION | ESSILOR INTERNATIONAL (FR) | 2023-07-13 | — | — | US | disclosed |
| US-9841652-B2 | Electrochromic composition | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2017-12-12 | — | — | US | disclosed |
| US-9841652-B2 | Electrochromic composition | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2017-12-12 | — | — | US | disclosed |
| US-9823534-B2 | Electrochromic single and two-core viologens and optical articles containing them | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2017-11-21 | — | — | US | disclosed |
| US-9785030-B2 | Electrochromic composition | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2017-10-10 | — | — | US | disclosed |
| US-9785030-B2 | Electrochromic composition | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2017-10-10 | — | — | US | disclosed |
| US-20160282694-A1 | ELECTROCHROMIC COMPOSITION | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2016-09-29 | — | — | US | disclosed |
| US-20160231635-A1 | ELECTROCHROMIC SINGLE AND TWO-CORE VIOLOGENS AND OPTICAL ARTICLES CONTAINING THEM | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2016-08-11 | — | — | US | disclosed |
| US-20160231636-A1 | ELECTROCHROMIC COMPOSITION | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2016-08-11 | — | — | US | disclosed |
| US-20160231636-A1 | ELECTROCHROMIC COMPOSITION | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160231635-A1 | ELECTROCHROMIC SINGLE AND TWO-CORE VIOLOGENS AND OPTICAL ARTICLES CONTAINING THEM | EYA2, CRY2, EYA3 | CA2 398/4885ALDH1A1 2566/4885TSHR 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.